Genmab — Februar 2018
-
Genmab-chef: »Vi tror på, at salget dybest set vil eksplodere«
2018 bliver et godt år, men 2019 kommer til at slå alle rekorder, forventer topchefen i Genmab. Trods 5,4 mia. kr. i kassebeholdning vil direktøren ikke videresende pengene til investorerne.
Finans (finans.dk)
-
En hidsig overskrift på den artikel.
-
Mere moderat her:
-
-
Det har vi vist efterhånden fundet ud af.
-
Janssen expanding its development program for the subcutaneous formulation of DARZALEX (daratumumab) with six planned and ongoing clinical studies. Halozyme's ENHANZE technology has the potential to enable a 15-ml injection to be delivered in five minutes or less. The ongoing or planned trials in patients with Amyloidosis, Smoldering Myeloma and Multiple Myeloma include four Phase 3 studies, one Phase 2 study and one Phase 1 study.
-
Mon ikke vi kan forvente nogle analytikere som melder højere kursmål ud? De har ellers været faldende i takt med aktien det sidste stykke tid.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind